HRP20201326T1 - Kombinacijska liječenja koja sadrže imidazopirazinone za liječenje psihijatrijskih i/ili kognitivnih poremećaja - Google Patents
Kombinacijska liječenja koja sadrže imidazopirazinone za liječenje psihijatrijskih i/ili kognitivnih poremećaja Download PDFInfo
- Publication number
- HRP20201326T1 HRP20201326T1 HRP20201326TT HRP20201326T HRP20201326T1 HR P20201326 T1 HRP20201326 T1 HR P20201326T1 HR P20201326T T HRP20201326T T HR P20201326TT HR P20201326 T HRP20201326 T HR P20201326T HR P20201326 T1 HRP20201326 T1 HR P20201326T1
- Authority
- HR
- Croatia
- Prior art keywords
- pyrazin
- methyl
- imidazo
- pyran
- tetrahydro
- Prior art date
Links
- 208000010877 cognitive disease Diseases 0.000 title claims 9
- 208000020016 psychiatric disease Diseases 0.000 title claims 7
- 238000011282 treatment Methods 0.000 title claims 5
- 238000011284 combination treatment Methods 0.000 title 1
- MPWOBEOETVOESI-UHFFFAOYSA-N imidazo[4,5-b]pyrazin-2-one Chemical class N1=CC=NC2=NC(=O)N=C21 MPWOBEOETVOESI-UHFFFAOYSA-N 0.000 title 1
- 125000001424 substituent group Chemical group 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 15
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 14
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 12
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 12
- 229910052736 halogen Inorganic materials 0.000 claims 10
- 150000002367 halogens Chemical group 0.000 claims 10
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000001153 fluoro group Chemical group F* 0.000 claims 8
- 150000002431 hydrogen Chemical class 0.000 claims 6
- 125000003566 oxetanyl group Chemical group 0.000 claims 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims 6
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims 6
- 125000001412 tetrahydropyranyl group Chemical group 0.000 claims 6
- 208000028698 Cognitive impairment Diseases 0.000 claims 4
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 4
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims 4
- -1 bicyclic ethers Chemical class 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 229910052731 fluorine Inorganic materials 0.000 claims 4
- 239000011737 fluorine Substances 0.000 claims 4
- LNEPOXFFQSENCJ-UHFFFAOYSA-N haloperidol Chemical compound C1CC(O)(C=2C=CC(Cl)=CC=2)CCN1CCCC(=O)C1=CC=C(F)C=C1 LNEPOXFFQSENCJ-UHFFFAOYSA-N 0.000 claims 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 4
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 201000000980 schizophrenia Diseases 0.000 claims 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims 2
- VSWBSWWIRNCQIJ-GJZGRUSLSA-N (R,R)-asenapine Chemical compound O1C2=CC=CC=C2[C@@H]2CN(C)C[C@H]2C2=CC(Cl)=CC=C21 VSWBSWWIRNCQIJ-GJZGRUSLSA-N 0.000 claims 2
- BGRJTUBHPOOWDU-NSHDSACASA-N (S)-(-)-sulpiride Chemical compound CCN1CCC[C@H]1CNC(=O)C1=CC(S(N)(=O)=O)=CC=C1OC BGRJTUBHPOOWDU-NSHDSACASA-N 0.000 claims 2
- ZNGWEEUXTBNKFR-UHFFFAOYSA-N 1,4-oxazepane Chemical compound C1CNCCOC1 ZNGWEEUXTBNKFR-UHFFFAOYSA-N 0.000 claims 2
- ISOFGIBMBLOJRH-UHFFFAOYSA-N 2-[[6-methyl-3-(oxan-4-yl)-8-oxoimidazo[1,5-a]pyrazin-7-yl]methyl]benzonitrile Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=C(C#N)C=CC=C1 ISOFGIBMBLOJRH-UHFFFAOYSA-N 0.000 claims 2
- SSOZXXUSHMYCRH-UHFFFAOYSA-N 3,3a,4,5,6,6a-hexahydro-2h-furo[3,2-b]pyrrole Chemical compound O1CCC2NCCC21 SSOZXXUSHMYCRH-UHFFFAOYSA-N 0.000 claims 2
- UOMHYPRQAMXYDQ-UHFFFAOYSA-N 3-(1,4-dimethylpiperidin-4-yl)-7-[(4-methoxyphenyl)methyl]-6-methylimidazo[1,5-a]pyrazin-8-one Chemical compound CN1CCC(CC1)(C)C1=NC=C2N1C=C(N(C2=O)CC1=CC=C(C=C1)OC)C UOMHYPRQAMXYDQ-UHFFFAOYSA-N 0.000 claims 2
- ANGLWHGRWFOZSQ-UHFFFAOYSA-N 3-(1-methoxy-2-methylpropan-2-yl)-7-[(4-methoxyphenyl)methyl]-6-methylimidazo[1,5-a]pyrazin-8-one Chemical compound COCC(C)(C)C1=NC=C2N1C=C(N(C2=O)CC1=CC=C(C=C1)OC)C ANGLWHGRWFOZSQ-UHFFFAOYSA-N 0.000 claims 2
- GEKRVCRUZXROSZ-UHFFFAOYSA-N 3-(2,2-difluorocyclopropyl)-7-[(3-fluorophenyl)methyl]-6-methylimidazo[1,5-a]pyrazin-8-one Chemical compound FC1(C(C1)C1=NC=C2N1C=C(N(C2=O)CC1=CC(=CC=C1)F)C)F GEKRVCRUZXROSZ-UHFFFAOYSA-N 0.000 claims 2
- HVRCNXOHZPZGSJ-UHFFFAOYSA-N 3-(2,2-dimethylmorpholin-4-yl)-7-[(4-methoxyphenyl)methyl]-6-methylimidazo[1,5-a]pyrazin-8-one Chemical compound CC1(OCCN(C1)C1=NC=C2N1C=C(N(C2=O)CC1=CC=C(C=C1)OC)C)C HVRCNXOHZPZGSJ-UHFFFAOYSA-N 0.000 claims 2
- IJXXNTVMDPJVBW-UHFFFAOYSA-N 3-(2,6-dimethyloxan-4-yl)-7-[(4-methoxyphenyl)methyl]-6-methylimidazo[1,5-a]pyrazin-8-one Chemical compound CC1OC(CC(C1)C1=NC=C2N1C=C(N(C2=O)CC1=CC=C(C=C1)OC)C)C IJXXNTVMDPJVBW-UHFFFAOYSA-N 0.000 claims 2
- DKRDXFRQADAIHU-UHFFFAOYSA-N 3-(2-fluoropropan-2-yl)-7-[(4-methoxyphenyl)methyl]-6-methylimidazo[1,5-a]pyrazin-8-one Chemical compound FC(C)(C)C1=NC=C2N1C=C(N(C2=O)CC1=CC=C(C=C1)OC)C DKRDXFRQADAIHU-UHFFFAOYSA-N 0.000 claims 2
- RVJAZKLTOAMCHB-UHFFFAOYSA-N 3-(2-hydroxypropan-2-yl)-7-[(4-methoxyphenyl)methyl]-6-methylimidazo[1,5-a]pyrazin-8-one Chemical compound OC(C)(C)C1=NC=C2N1C=C(N(C2=O)CC1=CC=C(C=C1)OC)C RVJAZKLTOAMCHB-UHFFFAOYSA-N 0.000 claims 2
- RQWUWJPTWQLWON-UHFFFAOYSA-N 3-(4-fluorooxan-4-yl)-7-[(3-fluorophenyl)methyl]-6-methylimidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)C2(CCOCC2)F)=O)C=CC=1 RQWUWJPTWQLWON-UHFFFAOYSA-N 0.000 claims 2
- COANVSPOSPBLGF-UHFFFAOYSA-N 3-(6-chloro-2,3-dihydro-1H-inden-1-yl)-7-[(4-methoxyphenyl)methyl]-6-methylimidazo[1,5-a]pyrazin-8-one Chemical compound ClC1=CC=C2CCC(C2=C1)C1=NC=C2N1C=C(N(C2=O)CC1=CC=C(C=C1)OC)C COANVSPOSPBLGF-UHFFFAOYSA-N 0.000 claims 2
- MVVQNOPLTGEXNR-UONOGXRCSA-N 3-[(1R,2R)-2-fluorocyclopropyl]-7-[(3-fluorophenyl)methyl]-6-methylimidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@@H]2[C@@H](C2)F)=O)C=CC=1 MVVQNOPLTGEXNR-UONOGXRCSA-N 0.000 claims 2
- MVVQNOPLTGEXNR-KBPBESRZSA-N 3-[(1R,2S)-2-fluorocyclopropyl]-7-[(3-fluorophenyl)methyl]-6-methylimidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@@H]2[C@H](C2)F)=O)C=CC=1 MVVQNOPLTGEXNR-KBPBESRZSA-N 0.000 claims 2
- MVVQNOPLTGEXNR-ZIAGYGMSSA-N 3-[(1S,2R)-2-fluorocyclopropyl]-7-[(3-fluorophenyl)methyl]-6-methylimidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@H]2[C@@H](C2)F)=O)C=CC=1 MVVQNOPLTGEXNR-ZIAGYGMSSA-N 0.000 claims 2
- MVVQNOPLTGEXNR-KGLIPLIRSA-N 3-[(1S,2S)-2-fluorocyclopropyl]-7-[(3-fluorophenyl)methyl]-6-methylimidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@H]2[C@H](C2)F)=O)C=CC=1 MVVQNOPLTGEXNR-KGLIPLIRSA-N 0.000 claims 2
- RZZDUEKLZBHEJJ-UHFFFAOYSA-N 3-[7-[(4-methoxyphenyl)methyl]-6-methyl-8-oxoimidazo[1,5-a]pyrazin-3-yl]-3-methylpyrrolidine-1-sulfonamide Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)C2(CN(CC2)S(=O)(=O)N)C)=O)C=C1 RZZDUEKLZBHEJJ-UHFFFAOYSA-N 0.000 claims 2
- HBKUUJGKQVTMIE-UHFFFAOYSA-N 3-[[6-methyl-3-(oxan-4-yl)-8-oxoimidazo[1,5-a]pyrazin-7-yl]methyl]benzonitrile Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC=1C=C(C#N)C=CC=1 HBKUUJGKQVTMIE-UHFFFAOYSA-N 0.000 claims 2
- XFBSUTIIWYEUPC-UHFFFAOYSA-N 3-cyclopropyl-7-[(3-fluorophenyl)methyl]imidazo[1,5-a]pyrazin-8-one Chemical compound C1(CC1)C1=NC=C2N1C=CN(C2=O)CC1=CC(=CC=C1)F XFBSUTIIWYEUPC-UHFFFAOYSA-N 0.000 claims 2
- PMXMIIMHBWHSKN-UHFFFAOYSA-N 3-{2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl}-9-hydroxy-2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCC(O)C4=NC=3C)=NOC2=C1 PMXMIIMHBWHSKN-UHFFFAOYSA-N 0.000 claims 2
- USXLZPZGBIYQLQ-UHFFFAOYSA-N 4-[7-[(3-fluorophenyl)methyl]-6-methyl-8-oxoimidazo[1,5-a]pyrazin-3-yl]oxane-4-carbonitrile Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)C2(CCOCC2)C#N)=O)C=CC=1 USXLZPZGBIYQLQ-UHFFFAOYSA-N 0.000 claims 2
- LQAZSSIUEDYCBP-UHFFFAOYSA-N 4-[[6-methyl-3-(oxan-4-yl)-8-oxoimidazo[1,5-a]pyrazin-7-yl]methyl]benzonitrile Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=CC=C(C#N)C=C1 LQAZSSIUEDYCBP-UHFFFAOYSA-N 0.000 claims 2
- SVVUZGLLATUKEM-UHFFFAOYSA-N 6,7-dimethyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)C SVVUZGLLATUKEM-UHFFFAOYSA-N 0.000 claims 2
- TUNXEGCQHJFZRL-UHFFFAOYSA-N 6-(cyclopentylmethyl)-7-[(4-methoxyphenyl)methyl]-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C1(CCCC1)CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=CC=C(C=C1)OC TUNXEGCQHJFZRL-UHFFFAOYSA-N 0.000 claims 2
- DDTRHXHSHXSEDF-UHFFFAOYSA-N 6-benzyl-7-(cyclohexylmethyl)-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C(C1=CC=CC=C1)C=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1CCCCC1 DDTRHXHSHXSEDF-UHFFFAOYSA-N 0.000 claims 2
- NTXQTICQWIKNOO-UHFFFAOYSA-N 6-benzyl-7-[(3-fluorophenyl)methyl]-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C(C1=CC=CC=C1)C=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=CC(=CC=C1)F NTXQTICQWIKNOO-UHFFFAOYSA-N 0.000 claims 2
- JVYBBFBHTBCHNY-UHFFFAOYSA-N 6-bromo-7-[(3-fluorophenyl)methyl]-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound BrC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=CC(=CC=C1)F JVYBBFBHTBCHNY-UHFFFAOYSA-N 0.000 claims 2
- AFONMYZRPMFJAB-UHFFFAOYSA-N 6-ethyl-7-[(3-fluorophenyl)methyl]-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C(C)C=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=CC(=CC=C1)F AFONMYZRPMFJAB-UHFFFAOYSA-N 0.000 claims 2
- IHHHPGCUSMYQHX-UHFFFAOYSA-N 6-ethyl-7-[(4-methoxyphenyl)methyl]-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C(C)C=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=CC=C(C=C1)OC IHHHPGCUSMYQHX-UHFFFAOYSA-N 0.000 claims 2
- SQDRHBKRJBDLOC-UHFFFAOYSA-N 6-methyl-3-(oxan-4-yl)-7-(1,3-thiazol-4-ylmethyl)imidazo[1,5-a]pyrazin-8-one Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC=1N=CSC=1 SQDRHBKRJBDLOC-UHFFFAOYSA-N 0.000 claims 2
- VRSLRMWKAICODM-UHFFFAOYSA-N 6-methyl-3-(oxan-4-yl)-7-(thiophen-3-ylmethyl)imidazo[1,5-a]pyrazin-8-one Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=CSC=C1 VRSLRMWKAICODM-UHFFFAOYSA-N 0.000 claims 2
- UNRQWEFTRALILW-UHFFFAOYSA-N 6-methyl-3-(oxan-4-yl)-7-[[4-(trifluoromethoxy)phenyl]methyl]imidazo[1,5-a]pyrazin-8-one Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=CC=C(C=C1)OC(F)(F)F UNRQWEFTRALILW-UHFFFAOYSA-N 0.000 claims 2
- BMVVKSPFTXQSSF-UHFFFAOYSA-N 6-methyl-3-(oxan-4-yl)-7-propan-2-ylimidazo[1,5-a]pyrazin-8-one Chemical compound C(C)(C)N1C(C=2N(C=C1C)C(=NC=2)C1CCOCC1)=O BMVVKSPFTXQSSF-UHFFFAOYSA-N 0.000 claims 2
- ARICWMJJQKCTDR-UHFFFAOYSA-N 6-methyl-3-(oxan-4-yl)-7-propylimidazo[1,5-a]pyrazin-8-one Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CCC ARICWMJJQKCTDR-UHFFFAOYSA-N 0.000 claims 2
- OEYDINZBWMRAIK-UHFFFAOYSA-N 6-methyl-7-(3-methylbutyl)-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C(CC(C)C)N1C(C=2N(C=C1C)C(=NC=2)C1CCOCC1)=O OEYDINZBWMRAIK-UHFFFAOYSA-N 0.000 claims 2
- SFJUWCCYAPWXBB-UHFFFAOYSA-N 6-methyl-7-[(2-methyl-1,3-thiazol-4-yl)methyl]-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC=1N=C(SC=1)C SFJUWCCYAPWXBB-UHFFFAOYSA-N 0.000 claims 2
- ICFZMMURQAUHKS-UHFFFAOYSA-N 6-methyl-7-[(2-methylphenyl)methyl]-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=C(C=CC=C1)C ICFZMMURQAUHKS-UHFFFAOYSA-N 0.000 claims 2
- ZKIKXHAKXUODEV-UHFFFAOYSA-N 6-methyl-7-[(3-methyl-1,2-oxazol-5-yl)methyl]-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=CC(=NO1)C ZKIKXHAKXUODEV-UHFFFAOYSA-N 0.000 claims 2
- FCLGCXKNDLJHGE-UHFFFAOYSA-N 6-methyl-7-[(3-methylphenyl)methyl]-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=CC(=CC=C1)C FCLGCXKNDLJHGE-UHFFFAOYSA-N 0.000 claims 2
- NJLBYLKOKZGPPW-UHFFFAOYSA-N 6-methyl-7-[(4-methylphenyl)methyl]-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=CC=C(C=C1)C NJLBYLKOKZGPPW-UHFFFAOYSA-N 0.000 claims 2
- GPWMWZXIKCDSMW-UHFFFAOYSA-N 6-methyl-7-[(5-methyl-1,2-oxazol-3-yl)methyl]-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=NOC(=C1)C GPWMWZXIKCDSMW-UHFFFAOYSA-N 0.000 claims 2
- SGRJQQJTJHBFTK-UHFFFAOYSA-N 7-(cycloheptylmethyl)-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C1(CCCCCC1)CN1C(C=2N(C=C1)C(=NC=2)C1CCOCC1)=O SGRJQQJTJHBFTK-UHFFFAOYSA-N 0.000 claims 2
- YIBKFYWXALCNMI-UHFFFAOYSA-N 7-(cycloheptylmethyl)-3-cyclopropylimidazo[1,5-a]pyrazin-8-one Chemical compound C1(CCCCCC1)CN1C(C=2N(C=C1)C(=NC=2)C1CC1)=O YIBKFYWXALCNMI-UHFFFAOYSA-N 0.000 claims 2
- FIIDAEWKLGRESO-UHFFFAOYSA-N 7-(cycloheptylmethyl)-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C1(CCCCCC1)CN1C(C=2N(C=C1C)C(=NC=2)C1CCOCC1)=O FIIDAEWKLGRESO-UHFFFAOYSA-N 0.000 claims 2
- XXIPRLNKXMMFIK-UHFFFAOYSA-N 7-(cyclohexylmethyl)-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C1(CCCCC1)CN1C(C=2N(C=C1)C(=NC=2)C1CCOCC1)=O XXIPRLNKXMMFIK-UHFFFAOYSA-N 0.000 claims 2
- MVICHLUMJUWVOO-UHFFFAOYSA-N 7-(cyclohexylmethyl)-3-cyclopropylimidazo[1,5-a]pyrazin-8-one Chemical compound C1(CCCCC1)CN1C(C=2N(C=C1)C(=NC=2)C1CC1)=O MVICHLUMJUWVOO-UHFFFAOYSA-N 0.000 claims 2
- XQZACXVVNPRUIZ-UHFFFAOYSA-N 7-(cyclohexylmethyl)-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C1(CCCCC1)CN1C(C=2N(C=C1C)C(=NC=2)C1CCOCC1)=O XQZACXVVNPRUIZ-UHFFFAOYSA-N 0.000 claims 2
- ZVDAZHCIEJDXMC-UHFFFAOYSA-N 7-(cyclohexylmethyl)-6-methyl-3-propylimidazo[1,5-a]pyrazin-8-one Chemical compound C1(CCCCC1)CN1C(C=2N(C=C1C)C(=NC=2)CCC)=O ZVDAZHCIEJDXMC-UHFFFAOYSA-N 0.000 claims 2
- YXPSIYIAHYJXGI-UHFFFAOYSA-N 7-(cyclopentylmethyl)-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C1(CCCC1)CN1C(C=2N(C=C1)C(=NC=2)C1CCOCC1)=O YXPSIYIAHYJXGI-UHFFFAOYSA-N 0.000 claims 2
- MUELWSVWNVCRNW-UHFFFAOYSA-N 7-(cyclopentylmethyl)-3-cyclopropylimidazo[1,5-a]pyrazin-8-one Chemical compound C1(CCCC1)CN1C(C=2N(C=C1)C(=NC=2)C1CC1)=O MUELWSVWNVCRNW-UHFFFAOYSA-N 0.000 claims 2
- IVIOKHSMYSCNPJ-UHFFFAOYSA-N 7-(cyclopentylmethyl)-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C1(CCCC1)CN1C(C=2N(C=C1C)C(=NC=2)C1CCOCC1)=O IVIOKHSMYSCNPJ-UHFFFAOYSA-N 0.000 claims 2
- RNBCFPQVHXWYQR-UHFFFAOYSA-N 7-[(2-chlorophenyl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound ClC1=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=CC=C1 RNBCFPQVHXWYQR-UHFFFAOYSA-N 0.000 claims 2
- HLXDXKMIVTXPEU-UHFFFAOYSA-N 7-[(2-ethylphenyl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C(C)C1=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=CC=C1 HLXDXKMIVTXPEU-UHFFFAOYSA-N 0.000 claims 2
- SGDZBPUOHUWTHZ-UHFFFAOYSA-N 7-[(2-fluorophenyl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound FC1=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=CC=C1 SGDZBPUOHUWTHZ-UHFFFAOYSA-N 0.000 claims 2
- MVNHOYJYJWAEEH-UHFFFAOYSA-N 7-[(3,5-dimethyl-1,2-oxazol-4-yl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound CC1=NOC(=C1CN1C(C=2N(C=C1C)C(=NC=2)C1CCOCC1)=O)C MVNHOYJYJWAEEH-UHFFFAOYSA-N 0.000 claims 2
- AKDKVOQBJMHADC-UHFFFAOYSA-N 7-[(3-chloro-4-methoxyphenyl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound ClC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=CC=1OC AKDKVOQBJMHADC-UHFFFAOYSA-N 0.000 claims 2
- FRYCFLNTERXYHU-UHFFFAOYSA-N 7-[(3-chlorophenyl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound ClC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=CC=1 FRYCFLNTERXYHU-UHFFFAOYSA-N 0.000 claims 2
- ZCVGFCXGAGKYHH-UHFFFAOYSA-N 7-[(3-fluorophenyl)methyl]-3-(4-methoxyoxan-4-yl)-6-methylimidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)C2(CCOCC2)OC)=O)C=CC=1 ZCVGFCXGAGKYHH-UHFFFAOYSA-N 0.000 claims 2
- KWKGJBUJSCDIAL-UHFFFAOYSA-N 7-[(3-fluorophenyl)methyl]-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2)C(=NC=3)C2CCOCC2)=O)C=CC=1 KWKGJBUJSCDIAL-UHFFFAOYSA-N 0.000 claims 2
- MUGBFEOWKYVLQV-UHFFFAOYSA-N 7-[(3-fluorophenyl)methyl]-3-propylimidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2)C(=NC=3)CCC)=O)C=CC=1 MUGBFEOWKYVLQV-UHFFFAOYSA-N 0.000 claims 2
- VCCNMXVKDHUXGT-UHFFFAOYSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-(1-methylcyclopropyl)imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)C2(CC2)C)=O)C=CC=1 VCCNMXVKDHUXGT-UHFFFAOYSA-N 0.000 claims 2
- MVBCAJXPQPBVSA-UHFFFAOYSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-(4-methyloxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)C2(CCOCC2)C)=O)C=CC=1 MVBCAJXPQPBVSA-UHFFFAOYSA-N 0.000 claims 2
- DOTFZTSFGIKARD-UHFFFAOYSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=CC=1 DOTFZTSFGIKARD-UHFFFAOYSA-N 0.000 claims 2
- NSFYZWGFIIQKQP-IAQYHMDHSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(1R,2R)-2-methylcyclopropyl]imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@H]2[C@@H](C2)C)=O)C=CC=1 NSFYZWGFIIQKQP-IAQYHMDHSA-N 0.000 claims 2
- NSFYZWGFIIQKQP-XHDPSFHLSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(1R,2S)-2-methylcyclopropyl]imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@H]2[C@H](C2)C)=O)C=CC=1 NSFYZWGFIIQKQP-XHDPSFHLSA-N 0.000 claims 2
- NSFYZWGFIIQKQP-ABAIWWIYSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(1S,2R)-2-methylcyclopropyl]imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@@H]2[C@@H](C2)C)=O)C=CC=1 NSFYZWGFIIQKQP-ABAIWWIYSA-N 0.000 claims 2
- NSFYZWGFIIQKQP-NHYWBVRUSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(1S,2S)-2-methylcyclopropyl]imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@@H]2[C@H](C2)C)=O)C=CC=1 NSFYZWGFIIQKQP-NHYWBVRUSA-N 0.000 claims 2
- HIARPVHIVVSVTG-QGZVFWFLSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(2R)-oxan-2-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound CC1=CN2C(=CN=C2[C@H]2CCCCO2)C(=O)N1CC1=CC(F)=CC=C1 HIARPVHIVVSVTG-QGZVFWFLSA-N 0.000 claims 2
- BZFPDTIGFMRZDI-CJNGLKHVSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(2R,3R)-2-methyloxolan-3-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@@H]2[C@H](OCC2)C)=O)C=CC=1 BZFPDTIGFMRZDI-CJNGLKHVSA-N 0.000 claims 2
- BZFPDTIGFMRZDI-CZUORRHYSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(2R,3S)-2-methyloxolan-3-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@H]2[C@H](OCC2)C)=O)C=CC=1 BZFPDTIGFMRZDI-CZUORRHYSA-N 0.000 claims 2
- HIARPVHIVVSVTG-KRWDZBQOSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(2S)-oxan-2-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@H]2OCCCC2)=O)C=CC=1 HIARPVHIVVSVTG-KRWDZBQOSA-N 0.000 claims 2
- BZFPDTIGFMRZDI-BBRMVZONSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(2S,3R)-2-methyloxolan-3-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@@H]2[C@@H](OCC2)C)=O)C=CC=1 BZFPDTIGFMRZDI-BBRMVZONSA-N 0.000 claims 2
- BZFPDTIGFMRZDI-XJKSGUPXSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(2S,3S)-2-methyloxolan-3-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@H]2[C@@H](OCC2)C)=O)C=CC=1 BZFPDTIGFMRZDI-XJKSGUPXSA-N 0.000 claims 2
- AQLHITNAEZNQJK-IBGZPJMESA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(3R)-3-methyloxolan-3-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound CC1=CN2C(=CN=C2[C@@]2(C)CCOC2)C(=O)N1CC1=CC(F)=CC=C1 AQLHITNAEZNQJK-IBGZPJMESA-N 0.000 claims 2
- PZKOOBRKCGIRJF-HNNXBMFYSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(3R)-oxan-3-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound CC1=CN2C(=CN=C2[C@H]2CCCOC2)C(=O)N1CC1=CC(F)=CC=C1 PZKOOBRKCGIRJF-HNNXBMFYSA-N 0.000 claims 2
- LEYPTBGWIKQYRW-AWEZNQCLSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(3R)-oxolan-3-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound CC1=CN2C(=CN=C2[C@H]2CCOC2)C(=O)N1CC1=CC(F)=CC=C1 LEYPTBGWIKQYRW-AWEZNQCLSA-N 0.000 claims 2
- AQLHITNAEZNQJK-LJQANCHMSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(3S)-3-methyloxolan-3-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@]2(COCC2)C)=O)C=CC=1 AQLHITNAEZNQJK-LJQANCHMSA-N 0.000 claims 2
- PZKOOBRKCGIRJF-OAHLLOKOSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(3S)-oxan-3-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@H]2COCCC2)=O)C=CC=1 PZKOOBRKCGIRJF-OAHLLOKOSA-N 0.000 claims 2
- LEYPTBGWIKQYRW-CQSZACIVSA-N 7-[(3-fluorophenyl)methyl]-6-methyl-3-[(3S)-oxolan-3-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound FC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@H]2COCC2)=O)C=CC=1 LEYPTBGWIKQYRW-CQSZACIVSA-N 0.000 claims 2
- OYBSUAILVMFPHS-UHFFFAOYSA-N 7-[(3-methoxyphenyl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound COC=1C=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=CC=1 OYBSUAILVMFPHS-UHFFFAOYSA-N 0.000 claims 2
- KTLRVQOJQCOTEE-UHFFFAOYSA-N 7-[(4-aminophenyl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound NC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=C1 KTLRVQOJQCOTEE-UHFFFAOYSA-N 0.000 claims 2
- MAIAHERKVFXOBQ-UHFFFAOYSA-N 7-[(4-chloro-3-methoxyphenyl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound ClC1=C(C=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=C1)OC MAIAHERKVFXOBQ-UHFFFAOYSA-N 0.000 claims 2
- YSJUCDCNAYRULZ-UHFFFAOYSA-N 7-[(4-chlorophenyl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound ClC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=C1 YSJUCDCNAYRULZ-UHFFFAOYSA-N 0.000 claims 2
- RVWGYNGTLDYNPU-UHFFFAOYSA-N 7-[(4-cyclopropyloxyphenyl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C1(CC1)OC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=C1 RVWGYNGTLDYNPU-UHFFFAOYSA-N 0.000 claims 2
- HTAKTLWSUKQRRS-UHFFFAOYSA-N 7-[(4-fluorophenyl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound FC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=C1 HTAKTLWSUKQRRS-UHFFFAOYSA-N 0.000 claims 2
- HWZIGTUHYHCMIT-UHFFFAOYSA-N 7-[(4-hydroxyphenyl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound OC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=C1 HWZIGTUHYHCMIT-UHFFFAOYSA-N 0.000 claims 2
- VCAGHSXTTDHBAV-UHFFFAOYSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-(1,4-oxazepan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)N2CCOCCC2)=O)C=C1 VCAGHSXTTDHBAV-UHFFFAOYSA-N 0.000 claims 2
- XKGOGXSNJQICIE-UHFFFAOYSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-(3-methyl-5-oxopyrrolidin-3-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)C2(CNC(C2)=O)C)=O)C=C1 XKGOGXSNJQICIE-UHFFFAOYSA-N 0.000 claims 2
- YTOUKKHZMQVQLZ-UHFFFAOYSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-(3-methyloxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)C2C(COCC2)C)=O)C=C1 YTOUKKHZMQVQLZ-UHFFFAOYSA-N 0.000 claims 2
- IHKCYYAPLNKUMM-UHFFFAOYSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-(5-methyloxolan-3-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)C2COC(C2)C)=O)C=C1 IHKCYYAPLNKUMM-UHFFFAOYSA-N 0.000 claims 2
- ZMTDJXQCSYULBW-UHFFFAOYSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-(7-oxoazepan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCNC(CC2)=O)=O)C=C1 ZMTDJXQCSYULBW-UHFFFAOYSA-N 0.000 claims 2
- PUKNFFAMUWZTGI-UHFFFAOYSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=C1 PUKNFFAMUWZTGI-UHFFFAOYSA-N 0.000 claims 2
- MVGJRDDRTHNROA-UHFFFAOYSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-(oxolan-3-ylamino)imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)NC2COCC2)=O)C=C1 MVGJRDDRTHNROA-UHFFFAOYSA-N 0.000 claims 2
- SWHFTCTZWOUUQD-QGZVFWFLSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-[(1R)-1-phenylethyl]imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@H](C)C2=CC=CC=C2)=O)C=C1 SWHFTCTZWOUUQD-QGZVFWFLSA-N 0.000 claims 2
- NRIDLTZEDZLZBY-KPLVRAHFSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-[(1R,2R,4S)-2-methyl-7-oxabicyclo[2.2.1]heptan-2-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@@]2([C@H]3CC[C@@H](C2)O3)C)=O)C=C1 NRIDLTZEDZLZBY-KPLVRAHFSA-N 0.000 claims 2
- SWHFTCTZWOUUQD-KRWDZBQOSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-[(1S)-1-phenylethyl]imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@@H](C)C2=CC=CC=C2)=O)C=C1 SWHFTCTZWOUUQD-KRWDZBQOSA-N 0.000 claims 2
- PZHZVFDPQAUVKV-PBHICJAKSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-[(2R,3R)-2-methyloxolan-3-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@@H]2[C@H](OCC2)C)=O)C=C1 PZHZVFDPQAUVKV-PBHICJAKSA-N 0.000 claims 2
- PZHZVFDPQAUVKV-RHSMWYFYSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-[(2R,3S)-2-methyloxolan-3-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@H]2[C@H](OCC2)C)=O)C=C1 PZHZVFDPQAUVKV-RHSMWYFYSA-N 0.000 claims 2
- PZHZVFDPQAUVKV-YOEHRIQHSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-[(2S,3R)-2-methyloxolan-3-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@@H]2[C@@H](OCC2)C)=O)C=C1 PZHZVFDPQAUVKV-YOEHRIQHSA-N 0.000 claims 2
- PZHZVFDPQAUVKV-WMLDXEAASA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-[(2S,3S)-2-methyloxolan-3-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)[C@H]2[C@@H](OCC2)C)=O)C=C1 PZHZVFDPQAUVKV-WMLDXEAASA-N 0.000 claims 2
- VQUWFLFKDYALSX-OAHLLOKOSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-[(3R)-3-methylmorpholin-4-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)N2[C@@H](COCC2)C)=O)C=C1 VQUWFLFKDYALSX-OAHLLOKOSA-N 0.000 claims 2
- VQUWFLFKDYALSX-HNNXBMFYSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-[(3S)-3-methylmorpholin-4-yl]imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)N2[C@H](COCC2)C)=O)C=C1 VQUWFLFKDYALSX-HNNXBMFYSA-N 0.000 claims 2
- XRYJHUBBBIIQDO-UHFFFAOYSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-[1-(4-methyl-1,3-thiazol-2-yl)ethyl]imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)C(C)C=2SC=C(N=2)C)=O)C=C1 XRYJHUBBBIIQDO-UHFFFAOYSA-N 0.000 claims 2
- DRHDVSISCJNWFF-UHFFFAOYSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-morpholin-4-ylimidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)N2CCOCC2)=O)C=C1 DRHDVSISCJNWFF-UHFFFAOYSA-N 0.000 claims 2
- RVHZRSIRMVWVKL-UHFFFAOYSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-propan-2-ylimidazo[1,5-a]pyrazin-8-one Chemical compound C(C)(C)C1=NC=C2N1C=C(N(C2=O)CC1=CC=C(C=C1)OC)C RVHZRSIRMVWVKL-UHFFFAOYSA-N 0.000 claims 2
- YMHRUXWRFFVZTC-UHFFFAOYSA-N 7-[(4-methoxyphenyl)methyl]-6-methyl-3-propylimidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)CCC)=O)C=C1 YMHRUXWRFFVZTC-UHFFFAOYSA-N 0.000 claims 2
- OVPVMIDVNMKKNU-UHFFFAOYSA-N 7-[(6-methoxypyridin-3-yl)methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound COC1=CC=C(C=N1)CN1C(C=2N(C=C1C)C(=NC=2)C1CCOCC1)=O OVPVMIDVNMKKNU-UHFFFAOYSA-N 0.000 claims 2
- ONRHTPIVLPKRAA-UHFFFAOYSA-N 7-[[4-(cyclopropylmethoxy)phenyl]methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C1(CC1)COC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=C1 ONRHTPIVLPKRAA-UHFFFAOYSA-N 0.000 claims 2
- QPWYRFGVZKZRGE-UHFFFAOYSA-N 7-[[4-(difluoromethoxy)phenyl]methyl]-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound FC(OC1=CC=C(CN2C(C=3N(C=C2C)C(=NC=3)C2CCOCC2)=O)C=C1)F QPWYRFGVZKZRGE-UHFFFAOYSA-N 0.000 claims 2
- LEQLMZLBAGAUDL-UHFFFAOYSA-N 7-benzyl-6-ethyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C(C1=CC=CC=C1)N1C(C=2N(C=C1CC)C(=NC=2)C1CCOCC1)=O LEQLMZLBAGAUDL-UHFFFAOYSA-N 0.000 claims 2
- JBXKPHLWRUHDIB-UHFFFAOYSA-N 7-benzyl-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C(C1=CC=CC=C1)N1C(C=2N(C=C1C)C(=NC=2)C1CCOCC1)=O JBXKPHLWRUHDIB-UHFFFAOYSA-N 0.000 claims 2
- WESIRYTURBTMCP-UHFFFAOYSA-N 7-ethyl-6-methyl-3-(oxan-4-yl)imidazo[1,5-a]pyrazin-8-one Chemical compound C(C)N1C(C=2N(C=C1C)C(=NC=2)C1CCOCC1)=O WESIRYTURBTMCP-UHFFFAOYSA-N 0.000 claims 2
- YPWFNLSXQIGJCK-UHFFFAOYSA-N 7-oxabicyclo[2.2.1]heptane Chemical compound C1CC2CCC1O2 YPWFNLSXQIGJCK-UHFFFAOYSA-N 0.000 claims 2
- 208000019901 Anxiety disease Diseases 0.000 claims 2
- CEUORZQYGODEFX-UHFFFAOYSA-N Aripirazole Chemical compound ClC1=CC=CC(N2CCN(CCCCOC=3C=C4NC(=O)CCC4=CC=3)CC2)=C1Cl CEUORZQYGODEFX-UHFFFAOYSA-N 0.000 claims 2
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 2
- XVGOZDAJGBALKS-UHFFFAOYSA-N Blonanserin Chemical compound C1CN(CC)CCN1C1=CC(C=2C=CC(F)=CC=2)=C(CCCCCC2)C2=N1 XVGOZDAJGBALKS-UHFFFAOYSA-N 0.000 claims 2
- PLDUPXSUYLZYBN-UHFFFAOYSA-N Fluphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C21 PLDUPXSUYLZYBN-UHFFFAOYSA-N 0.000 claims 2
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 claims 2
- NPFWMFUXABVSFE-UHFFFAOYSA-N N-[4-[[6-methyl-3-(oxan-4-yl)-8-oxoimidazo[1,5-a]pyrazin-7-yl]methyl]phenyl]acetamide Chemical compound CC=1N(C(C=2N(C=1)C(=NC=2)C1CCOCC1)=O)CC1=CC=C(C=C1)NC(C)=O NPFWMFUXABVSFE-UHFFFAOYSA-N 0.000 claims 2
- RGCVKNLCSQQDEP-UHFFFAOYSA-N Perphenazine Chemical compound C1CN(CCO)CCN1CCCN1C2=CC(Cl)=CC=C2SC2=CC=CC=C21 RGCVKNLCSQQDEP-UHFFFAOYSA-N 0.000 claims 2
- 229960003036 amisulpride Drugs 0.000 claims 2
- NTJOBXMMWNYJFB-UHFFFAOYSA-N amisulpride Chemical compound CCN1CCCC1CNC(=O)C1=CC(S(=O)(=O)CC)=C(N)C=C1OC NTJOBXMMWNYJFB-UHFFFAOYSA-N 0.000 claims 2
- 230000036506 anxiety Effects 0.000 claims 2
- 229960004372 aripiprazole Drugs 0.000 claims 2
- 229960005245 asenapine Drugs 0.000 claims 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 2
- 229950002871 blonanserin Drugs 0.000 claims 2
- 229960001210 brexpiprazole Drugs 0.000 claims 2
- ZKIAIYBUSXZPLP-UHFFFAOYSA-N brexpiprazole Chemical compound C1=C2NC(=O)C=CC2=CC=C1OCCCCN(CC1)CCN1C1=CC=CC2=C1C=CS2 ZKIAIYBUSXZPLP-UHFFFAOYSA-N 0.000 claims 2
- 229960005123 cariprazine Drugs 0.000 claims 2
- KPWSJANDNDDRMB-QAQDUYKDSA-N cariprazine Chemical compound C1C[C@@H](NC(=O)N(C)C)CC[C@@H]1CCN1CCN(C=2C(=C(Cl)C=CC=2)Cl)CC1 KPWSJANDNDDRMB-QAQDUYKDSA-N 0.000 claims 2
- 229960001076 chlorpromazine Drugs 0.000 claims 2
- ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 claims 2
- NJMYODHXAKYRHW-DVZOWYKESA-N cis-flupenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(C(F)(F)F)=CC=C2SC2=CC=CC=C2/1 NJMYODHXAKYRHW-DVZOWYKESA-N 0.000 claims 2
- 229960004170 clozapine Drugs 0.000 claims 2
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 2
- 125000004428 fluoroalkoxy group Chemical group 0.000 claims 2
- 229960002419 flupentixol Drugs 0.000 claims 2
- 229960002690 fluphenazine Drugs 0.000 claims 2
- 229960003878 haloperidol Drugs 0.000 claims 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 2
- 229960003162 iloperidone Drugs 0.000 claims 2
- XMXHEBAFVSFQEX-UHFFFAOYSA-N iloperidone Chemical compound COC1=CC(C(C)=O)=CC=C1OCCCN1CCC(C=2C3=CC=C(F)C=C3ON=2)CC1 XMXHEBAFVSFQEX-UHFFFAOYSA-N 0.000 claims 2
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 claims 2
- 150000003951 lactams Chemical class 0.000 claims 2
- 229960001432 lurasidone Drugs 0.000 claims 2
- PQXKDMSYBGKCJA-CVTJIBDQSA-N lurasidone Chemical compound C1=CC=C2C(N3CCN(CC3)C[C@@H]3CCCC[C@H]3CN3C(=O)[C@@H]4[C@H]5CC[C@H](C5)[C@@H]4C3=O)=NSC2=C1 PQXKDMSYBGKCJA-CVTJIBDQSA-N 0.000 claims 2
- 229940042053 methotrimeprazine Drugs 0.000 claims 2
- VRQVVMDWGGWHTJ-CQSZACIVSA-N methotrimeprazine Chemical compound C1=CC=C2N(C[C@H](C)CN(C)C)C3=CC(OC)=CC=C3SC2=C1 VRQVVMDWGGWHTJ-CQSZACIVSA-N 0.000 claims 2
- 125000002950 monocyclic group Chemical group 0.000 claims 2
- 201000003631 narcolepsy Diseases 0.000 claims 2
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 2
- 229960005017 olanzapine Drugs 0.000 claims 2
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 claims 2
- MIPHRQMEIYLZFZ-UHFFFAOYSA-N oxolan-3-amine Chemical compound NC1CCOC1 MIPHRQMEIYLZFZ-UHFFFAOYSA-N 0.000 claims 2
- 229960001057 paliperidone Drugs 0.000 claims 2
- 229960000762 perphenazine Drugs 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 125000004076 pyridyl group Chemical group 0.000 claims 2
- 229960004431 quetiapine Drugs 0.000 claims 2
- URKOMYMAXPYINW-UHFFFAOYSA-N quetiapine Chemical compound C1CN(CCOCCO)CCN1C1=NC2=CC=CC=C2SC2=CC=CC=C12 URKOMYMAXPYINW-UHFFFAOYSA-N 0.000 claims 2
- 229960001534 risperidone Drugs 0.000 claims 2
- RAPZEAPATHNIPO-UHFFFAOYSA-N risperidone Chemical compound FC1=CC=C2C(C3CCN(CC3)CCC=3C(=O)N4CCCCC4=NC=3C)=NOC2=C1 RAPZEAPATHNIPO-UHFFFAOYSA-N 0.000 claims 2
- 229940124530 sulfonamide Drugs 0.000 claims 2
- 150000003456 sulfonamides Chemical group 0.000 claims 2
- 229960004940 sulpiride Drugs 0.000 claims 2
- 229960000607 ziprasidone Drugs 0.000 claims 2
- MVWVFYHBGMAFLY-UHFFFAOYSA-N ziprasidone Chemical compound C1=CC=C2C(N3CCN(CC3)CCC3=CC=4CC(=O)NC=4C=C3Cl)=NSC2=C1 MVWVFYHBGMAFLY-UHFFFAOYSA-N 0.000 claims 2
- 229960004141 zuclopenthixol Drugs 0.000 claims 2
- WFPIAZLQTJBIFN-DVZOWYKESA-N zuclopenthixol Chemical compound C1CN(CCO)CCN1CC\C=C\1C2=CC(Cl)=CC=C2SC2=CC=CC=C2/1 WFPIAZLQTJBIFN-DVZOWYKESA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (10)
1. Spoj Formule (I)
[image]
pri čemu
n je 0 ili 1;
q je 0 ili 1;
R1 je odabran od skupine koja se sastoji od benzila, indanila, indolina i 5-članih heteroarila; od kojih svi mogu biti supstituirani sa supstituentom odabranim od skupine koja se sastoji od halogena i C1-C3 alkila; ili
R1 je odabran od skupine koja se sastoji od zasićenih monocikličnih prstena koji sadrže 4-6 atoma ugljika i 1-2 atoma dušika; od kojih svi mogu biti supstituirani jednom ili više puta s jednim ili više supstituenata odabranih od skupine koja se sastoji od metila, fluora i sulfonamida; ili
R1 je odabran od skupine koja se sastoji od laktama koji sadrže 4-6 atoma ugljika; od kojih svi mogu biti supstituirani jednom ili više puta s jednim ili više supstituenata odabranih od skupine koja se sastoji od metila i fluora; ili
R1 je odabran od skupine koja se sastoji od bicikličnih etera poput 7-oksabiciklo[2.2.1]heptana; od kojih svi mogu biti supstituirani jednom ili više puta s jednim ili više supstituenata odabranih od skupine koja se sastoji od metila i fluora; ili
R1 je odabran od skupine koja se sastoji od linearnog ili razgranatog C1-C8 alkila, zasićenog monocikličnog C3-C8 cikloalkila, oksetanila, tetrahidrofuranila i tetrahidropiranila; od kojih svi mogu biti supstituirani jednom ili više puta s jednim ili više supstituenata odabranih od skupine koja se sastoji od metila, fluora, hidroksi, cijano ili metoksi; ili
R1 je linearni ili razgranati C1-C3 alkil, koji je supstituiran sa supstituentom odabranim od fenila i 5-članog heteroarila, pri čemu spomenuti 5-člani heteroaril može biti supstituiran s jednim ili više C1-C3 alkila; ili
R1 je odabran od skupine koja se sastoji od morfolina, tetrahidrofuran-3-amina, heksahidro-2H-furo[3,2-b)pirola i homomorfolina; od kojih svi mogu biti supstituirani s jednim ili više supstituenata odabranih od skupine koja se sastoji od C1-C3 alkila;
R2 je odabran od skupine koja se sastoji od vodika, linearnog ili razgranatog C1-C8 alkila, fenila, zasićenog monocikličnog C3-C8 cikloalkila, oksetanila, benzo[d][1,3]dioksolila, tetrahidrofuranila i tetrahidropiranila; ili
R2 je fenil ili piridil supstituiran s jednim ili više supstituenata odabranih od skupine koja se sastoji od hidroksila, amino, cijano, halogena, C1-C3 alkila, C1-C3 alkoksi, C3-C5 cikloalkoksi, C3-C5 cikloalkil-metoksi, C1-C3 fluoroalkoksi, i -NC(O)CH3; ili
R2 je 5-člani heteroaril koji može biti supstituiran s jednim ili više C1-C3 alkila;
R3 je odabran od skupine koja se sastoji od vodika, halogena, C1-C5 alkila, C3-C5 cikloalkila i fenila; ili
R3 je odabran od skupine koja se sastoji od fenila supstituiranog jednom ili više puta s C1-C3 alkilom; metila supstituiranog jednom, dva ili tri puta s fluorom; etila supstituiranog jednom, dva ili tri puta s fluorom;
R4 je vodik;
i njegovi tautomeri i farmaceutski prihvatljive adicijske soli;
pod uvjetom da R2 i R3 ne mogu biti vodik u isto vrijeme; i
2) drugi spoj, koji je koristan u liječenju psihijatrijskog poremećaja, pri čemu je spomenuti drugi spoj odabran s popisa koji se sastoji od klozapina, risperidona, paliperidona, olanzapina, kvetiapina, amisulprida, ziprasidona, aripiprazola, brekspiprazola, asenapina, haloperidola, iloperidona, lurasidona, klorpromazina, blonanserina, perfenazina, levomepromazina, sulpirida, flufenazina, zuklopentiksola, flupentiksola i kariprazina; pri čemu su 1) i 2) za kombiniranu primjenu u liječenju psihijatrijskog i/ili kognitivnog poremećaja.
2. Spojevi za uporabu prema zahtjevu 1, pri čemu
R1 je odabran od skupine koja se sastoji od linearnog ili razgranatog C1-C8 alkila, zasićenog monocikličnog C3-C8 cikloalkila, oksetanila, tetrahidrofuranila, i tetrahidropiranila;
R2 je odabran od skupine koja se sastoji od linearnog ili razgranatog C1-C8 alkila, fenila, i zasićenog monocikličnog C3-C8 cikloalkila; ili
R2 je odabran od skupine koja se sastoji od fenila supstituiranog sa supstituentom odabranim od skupine koja se sastoji od halogena, C1-C3 alkila i metoksi;
R3 je odabran od skupine koja se sastoji od vodika, C1-C3 alkila i halogena;
R4 je vodik.
3. Spojevi za uporabu prema zahtjevu 1, pri čemu je spomenuti spoj formule (I) odabran od skupine koja se sastoji od:
7-(3-Fluorobenzil)-3-propilimidazo[1,5-a]pirazin-8(7H)-on;
6-Benzil-7-(3-fluorobenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-Benzil-7-(cikloheksilmetil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(Cikloheksilmetil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-Fluorobenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
3-Ciklopropil-7-(3-fluorobenzil)imidazo[1,5-a]pirazin-8(7H)-on;
7-(Ciklopentilmetil)-3-ciklopropilimidazo[1,5-a]pirazin-8(7H)-on;
7-(Cikloheksilmetil)-3-ciklopropilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-Fluorobenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(Ciklopentilmetil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(Cikloheksilmetil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(Cikloheptilmetil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(Cikloheptilmetil)-3-ciklopropilimidazo[1,5-a]pirazin-8(7H)-on;
7-(4-Klorobenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-Bromo-7-(3-fluorobenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-Benzil-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(2-Fluorobenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-Klorobenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(2-Klorobenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-Metoksibenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-Metil-7-(2-metilbenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-Metil-7-(4-metilbenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-Metoksibenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-Fluorobenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-Metil-7-(3-metilbenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-(4-metiltetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
4-(7-(3-fluorobenzil)-6-metil-8-okso-7,8-dihidroimidazo[1,5-a]pirazin-3-il)tetrahidro-2H-piran-4-karbonitril;
7-(3-fluorobenzil)-3-(4-metoksitetrahidro-2H-piran-4-il)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-3-(4-fluorotetrahidro-2H-piran-4-il)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
(R)-7-(3-fluorobenzil)-6-metil-3-(tetrahidro-2H-piran-2-il)imidazo[1,5-a]pirazin-8(7H)-on;
(S)-7-(3-fluorobenzil)-6-metil-3-(tetrahidro-2H-piran-2-il)imidazo[1,5-a]pirazin-8(7H)-on;
(R)-7-(3-fluorobenzil)-6-metil-3-(tetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
(S)-7-(3-fluorobenzil)-6-metil-3-(tetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
(R)-7-(3-fluorobenzil)-6-metil-3-(3-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
(S)-7-(3-fluorobenzil)-6-metil-3-(3-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-(1-metilciklopropil)imidazo[1,5-a]pirazin-8(7H)-on;
3-(2,2-difluorociklopropil)-7-(3-fluorobenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((1R,2S)-2-metilciklopropil)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((1R,2R)-2-metilciklopropil)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((1S,2S)-2-metilciklopropil)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((1S,2R)-2-metilciklopropil)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((2S,3R)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((2S,3S)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((2R,3R)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((2R,3S)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-3-((1R,2S)-2-fluorociklopropil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-3-((1R,2R)-2-fluorociklopropil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-3-((1S,2S)-2-fluorociklopropil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-3-((1S,2R)-2-fluorociklopropil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(4-ciklopropoksibenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-(difluorometoksi)benzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-metil-3-(tetrahidro-2H-piran-4-il)-7-(4-(trifluorometoksi)benzil)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-(ciklopropilmetoksi)benzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-benzil-6-etil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-etil-7-(4-metoksibenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
3-((6-metil-8-okso-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-7(8H)-il)metil)benzonitril;
4-((6-metil-8-okso-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-7(8H)-il)metil)benzonitril;
N-(4-((6-metil-8-okso-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-7(8H)-il)metil)fenil)acetamid;
7-(4-kloro-3-metoksibenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(2-etilbenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(benzo[d][1,3]dioksol-5-ilmetil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-kloro-4-metoksibenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-aminobenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-hidroksibenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-etil-7-(3-fluorobenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-((2S,3R)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-((2S,3S)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-((2R,3R)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-((2R,3S)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-propilimidazo[1,5-a]pirazin-8(7H)-on;
7-((6-metoksipiridin-3-il)metil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6,7-dimetil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-etil-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-metil-7-propil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-izopropil-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-izopentil-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(ciklopentilmetil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
2-((6-metil-8-okso-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-7(8H)-il)metil)benzonitril;
7-(cikloheptilmetil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-(3-metiltetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-((1R,2R,4S)-2-metil-7-oksabiciklo[2.2.1]heptan-2-il)imidazo[1,5-a]pirazin-8(7H)-on;
(S)-7-(4-metoksibenzil)-6-metil-3-(1-feniletil)imidazo[1,5-a]pirazin-8(7H)-on;
(R)-7-(4-metoksibenzil)-6-metil-3-(1-feniletil)imidazo[1,5-a]pirazin-8(7H)-on;
3-(1,4-dimetilpiperidin-4-il)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
3-(6-kloro-2,3-dihidro-1H-inden-1-il)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-(3-metil-5-oksopirolidin-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
3-(1-metoksi-2-metilpropan-2-il)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
3-izopropil-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
6-metil-7-((2-metiltiazol-4-il)metil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-metil-3-(tetrahidro-2H-piran-4-il)-7-(tiofen-3-ilmetil)imidazo[1,5-a]pirazin-8(7H)-on;
6-metil-3-(tetrahidro-2H-piran-4-il)-7-(tiazol-4-ilmetil)imidazo[1,5-a]pirazin-8(7H)-on;
7-((3,5-dimetilizoksazol-4-il)metil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-metil-7-((5-metilizoksazol-3-il)metil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-metil-7-((3-metilizoksazol-5-il)metil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
3-(2,6-dimetiltetrahidro-2H-piran-4-il)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(cikloheksilmetil)-6-metil-3-propilimidazo[1,5-a]pirazin-8(7H)-on;
3-(2-hidroksipropan-2-il)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
3-(2-fluoropropan-2-il)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-(7-oksoazepan-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-(5-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-(1-(4-metiltiazol-2-il)etil)imidazo[1,5-a]pirazin-8(7H)-on;
3-(7-(4-metoksibenzil)-6-metil-8-okso-7,8-dihidroimidazo[1,5-a]pirazin-3-il)-3-metilpirolidin-1-sulfonamid;
6-(ciklopentilmetil)-7-(4-metoksibenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
3-(morfolino)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-((tetrahidrofuran-3-il)amino)imidazo[1,5-a]pirazin-8(7H)-on;
(R)-7-(4-metoksibenzil)-6-metil-3-(3-metilmorfolino)imidazo[1,5-a]pirazin-8(7H)-on;
(S)-7-(4-metoksibenzil)-6-metil-3-(3-metilmorfolino)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-(1,4-oksazepan-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
3-(2,2-dimetilmorfolino)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-3-((3aS,6aS)-heksahidro-4H-furo[3,2-b]pirol-4-il)-6-etilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-3-((3aR,6aR)-heksahidro-4H-furo[3,2-b]pirol-4-il)-6-etilimidazo[1,5-a]pirazin-8(7H)-on;
(R)-7-(3-fluorobenzil)-6-metil-3-(tetrahidro-2H-piran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
(S)-7-(3-fluorobenzil)-6-metil-3-(tetrahidro-2H-piran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
ili farmaceutski prihvatljiva sol bilo kojeg od ovih spojeva.
4. Spojevi za uporabu prema bilo kojem od zahtjeva 1-3, pri čemu je spomenuti psihijatrijski i/ili kognitivni poremećaj odabran od skupine koja se sastoji od poremećaja hiperaktivnosti i deficita pažnje (ADHD), depresije, anksioznosti, narkolepsije, shizofrenije, kognitivnog oštećenja i kognitivnog oštećenja povezanog sa shizofrenijom (CIAS).
5. Farmaceutski pripravak koji sadrži:
1) spoj Formule (I)
[image]
pri čemu
n je 0 ili 1;
q je 0 ili 1:
R1 je odabran od skupine koja se sastoji od benzila, indanila, indolina i 5-članih heteroarila; od kojih svi mogu biti supstituirani sa supstituentom odabranim od skupine koja se sastoji od halogena i C1-C3 alkila; ili
R1 je odabran od skupine koja se sastoji od zasićenih monocikličnih prstena koji sadrže 4-6 atoma ugljika i 1-2 atoma dušika; od kojih svi mogu biti supstituirani jednom ili više puta s jednim ili više supstituenata odabranih od skupine koja se sastoji od metila, fluora i sulfonamida; ili
R1 je odabran od skupine koja se sastoji od laktama koji sadrže 4-6 atoma ugljika; od kojih svi mogu biti supstituirani jednom ili više puta s jednim ili više supstituenata odabranih od skupine koja se sastoji od metila i fluora; ili
R1 je odabran od skupine koja se sastoji od bicikličnih etera poput 7-oksabiciklo[2.2.1]heptana; od kojih svi mogu biti supstituirani jednom ili više puta s jednim ili više supstituenata odabranih od skupine koja se sastoji od metila i fluora; ili
R1 je odabran od skupine koja se sastoji od linearnog ili razgranatog C1-C8 alkila, zasićenog monocikličnog C3-C8 cikloalkila, oksetanila, tetrahidrofuranila i tetrahidropiranila; od kojih svi mogu biti supstituirani jednom ili više puta s jednim ili više supstituenata odabranih od skupine koja se sastoji od metila, fluora, hidroksi, cijano ili metoksi; ili
R1 je linearni ili razgranati C1-C3 alkil, koji je supstituiran sa supstituentom odabranim od fenila i 5-članog heteroarila, pri čemu spomenuti 5-člani heteroaril može biti supstituiran s jednim ili više C1-C3 alkila, ili
R1 je odabran od skupine koja se sastoji od morfolina, tetrahidrofuran-3-amina, heksahidro-2H-furo[3,2-b)pirola i homomorfolina; od kojih svi mogu biti supstituirani s jednim ili više supstituenata odabranih od skupine koja se sastoji od C1-C3 alkila;
R2 je odabran od skupine koja se sastoji od vodika, linearnog ili razgranatog C1-C8 alkila, fenila, zasićenog monocikličnog C3-C8 cikloalkila, oksetanila, benzo[d][1,3]dioksolila, tetrahidrofuranila i tetrahidropiranila; ili
R2 je fenil ili piridil supstituiran s jednim ili više supstituenata odabranih od skupine koja se sastoji od hidroksila, amino, cijano, halogena, C1-C3 alkila, C1-C3 alkoksi, C3-C5 cikloalkoksi, C3-C5 cikloalkil-metoksi, C1-C3 fluoroalkoksi, i -NC(O)CH3; ili
R2 je 5-člani heteroaril koji može biti supstituiran s jednim ili više C1-C3 alkila;
R3 je odabran od skupine koja se sastoji od vodika, halogena, C1-C5 alkila, C3-C5 cikloalkila i fenila; ili
R3 je odabran od skupine koja se sastoji od fenila supstituiranog jednom ili više puta s C1-C3 alkilom; metila supstituiranog jednom, dva ili tri puta s fluorom; etila supstituiranog jednom, dva ili tri puta s fluorom;
R4 je vodik;
i njegovi tautomeri i farmaceutski prihvatljive adicijske soli;
pod uvjetom da R2 i R3 ne mogu biti vodik u isto vrijeme; i
2) drugi spoj, koji je koristan u liječenju psihijatrijskog poremećaja pri čemu je spomenuti drugi spoj odabran s popisa koji se sastoji od klozapina, risperidona, paliperidona, olanzapina, kvetiapina, amisulprida, ziprasidona, aripiprazola, brekspiprazola, asenapina, haloperidola, iloperidona, lurasidona, klorpromazina, blonanserina, perfenazina, levomepromazina, sulpirida, flufenazina, zuklopentiksola, flupentiksola i kariprazina; i jedan ili više farmaceutski prihvatljivih nosača, razrjeđivača i pomoćnih tvari.
6. Farmaceutski pripravak prema zahtjevu 5, pri čemu
R1 je odabran od skupine koja se sastoji od linearnog ili razgranatog C1-C8 alkila, zasićenog monocikličnog C3-C8 cikloalkila, oksetanila, tetrahidrofuranila, i tetrahidropiranila;
R2 je odabran od skupine koja se sastoji od linearnog ili razgranatog C1-C8 alkila, fenila, i zasićenog monocikličnog C3-C8 cikloalkila; ili
R2 je odabran od skupine koja se sastoji od fenila supstituiranog sa supstituentom odabranim od skupine koja se sastoji od halogena, C1-C3 alkila i metoksi;
R3 je odabran od skupine koja se sastoji od vodika, C1-C3 alkila i halogena;
R4 je vodik.
7. Farmaceutski pripravak prema zahtjevu 5, pri čemu je spoj formule (I) odabran od skupine koja se sastoji od:
7-(3-Fluorobenzil)-3-propilimidazo[1,5-a]pirazin-8(7H)-on;
6-Benzil-7-(3-fluorobenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-Benzil-7-(cikloheksilmetil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(Cikloheksilmetil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on; 7-(3-Fluorobenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
3-Ciklopropil-7-(3-fluorobenzil)imidazo[1,5-a]pirazin-8(7H)-on;
7-(Ciklopentilmetil)-3-ciklopropilimidazo[1,5-a]pirazin-8(7H)-on;
7-(Cikloheksilmetil)-3-ciklopropilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-Fluorobenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(Ciklopentilmetil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(Cikloheksilmetil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(Cikloheptilmetil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(Cikloheptilmetil)-3-ciklopropilimidazo[1,5-a]pirazin-8(7H)-on;
7-(4-Klorobenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-Bromo-7-(3-fluorobenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-Benzil-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(2-Fluorobenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-Klorobenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(2-Klorobenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-Metoksibenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-Metil-7-(2-metilbenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-Metil-7-(4-metilbenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-Metoksibenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-Fluorobenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-Metil-7-(3-metilbenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-(4-metiltetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
4-(7-(3-fluorobenzil)-6-metil-8-okso-7,8-dihidroimidazo[1,5-a]pirazin-3-il)tetrahidro-2H-piran-4-karbonitril;
7-(3-fluorobenzil)-3-(4-metoksitetrahidro-2H-piran-4-il)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-3-(4-fluorotetrahidro-2H-piran-4-il)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
(R)-7-(3-fluorobenzil)-6-metil-3-(tetrahidro-2H-piran-2-il)imidazo[1,5-a]pirazin-8(7H)-on;
(S)-7-(3-fluorobenzil)-6-metil-3-(tetrahidro-2H-piran-2-il)imidazo[1,5-a]pirazin-8(7H)-on;
(R)-7-(3-fluorobenzil)-6-metil-3-(tetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
(S)-7-(3-fluorobenzil)-6-metil-3-(tetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
(R)-7-(3-fluorobenzil)-6-metil-3-(3-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
(S)-7-(3-fluorobenzil)-6-metil-3-(3-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-(1-metilciklopropil)imidazo[1,5-a]pirazin-8(7H)-on;
3-(2,2-difluorociklopropil)-7-(3-fluorobenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((1R,2S)-2-metilciklopropil)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((1R,2R)-2-metilciklopropil)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((1S,2S)-2-metilciklopropil)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((1S,2R)-2-metilciklopropil)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((2S,3R)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((2S,3S)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((2R,3R)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-6-metil-3-((2R,3S)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-3-((1R,2S)-2-fluorociklopropil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-3-((1R,2R)-2-fluorociklopropil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-3-((1S,2S)-2-fluorociklopropil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-3-((1S,2R)-2-fluorociklopropil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(4-ciklopropoksibenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-(difluorometoksi)benzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-metil-3-(tetrahidro-2H-piran-4-il)-7-(4-(trifluorometoksi)benzil)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-(ciklopropilmetoksi)benzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-benzil-6-etil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-etil-7-(4-metoksibenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
3-((6-metil-8-okso-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-7(8H)-il)metil)benzonitril;
4-((6-metil-8-okso-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-7(8H)-il)metil)benzonitril;
N-(4-((6-metil-8-okso-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-7(8H)-il)metil)fenil)acetamid;
7-(4-kloro-3-metoksibenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(2-etilbenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(benzo[d][1,3]dioksol-5-ilmetil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(3-kloro-4-metoksibenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-aminobenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-hidroksibenzil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-etil-7-(3-fluorobenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-((2S,3R)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-((2S,3S)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-((2R,3R)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-((2R,3S)-2-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-propilimidazo[1,5-a]pirazin-8(7H)-on;
7-((6-metoksipiridin-3-il)metil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6,7-dimetil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-etil-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-metil-7-propil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-izopropil-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-izopentil-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(ciklopentilmetil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
2-((6-metil-8-okso-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-7(8H)-il)metil)benzonitril;
7-(cikloheptilmetil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-(3-metiltetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-((1R,2R,4S)-2-metil-7-oksabiciklo[2.2.1]heptan-2-il)imidazo[1,5-a]pirazin-8(7H)-on;
(S)-7-(4-metoksibenzil)-6-metil-3-(1-feniletil)imidazo[1,5-a]pirazin-8(7H)-on;
(R)-7-(4-metoksibenzil)-6-metil-3-(1-feniletil)imidazo[1,5-a]pirazin-8(7H)-on;
3-(1,4-dimetilpiperidin-4-il)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
3-(6-kloro-2,3-dihidro-1H-inden-1-il)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-(3-metil-5-oksopirolidin-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
3-(1-metoksi-2-metilpropan-2-il)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
3-izopropil-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
6-metil-7-((2-metiltiazol-4-il)metil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-metil-3-(tetrahidro-2H-piran-4-il)-7-(tiofen-3-ilmetil)imidazo[1,5-a]pirazin-8(7H)-on;
6-metil-3-(tetrahidro-2H-piran-4-il)-7-(tiazol-4-ilmetil)imidazo[1,5-a]pirazin-8(7H)-on;
7-((3,5-dimetilizoksazol-4-il)metil)-6-metil-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-metil-7-((5-metilizoksazol-3-il)metil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
6-metil-7-((3-metilizoksazol-5-il)metil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
3-(2,6-dimetiltetrahidro-2H-piran-4-il)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(cikloheksilmetil)-6-metil-3-propilimidazo[1,5-a]pirazin-8(7H)-on;
3-(2-hidroksipropan-2-il)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
3-(2-fluoropropan-2-il)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-(7-oksoazepan-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-(5-metiltetrahidrofuran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-(1-(4-metiltiazol-2-il)etil)imidazo[1,5-a]pirazin-8(7H)-on;
3-(7-(4-metoksibenzil)-6-metil-8-okso-7,8-dihidroimidazo[1,5-a]pirazin-3-il)-3-metilpirolidin-1-sulfonamid;
6-(ciklopentilmetil)-7-(4-metoksibenzil)-3-(tetrahidro-2H-piran-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
3-(morfolino)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-((tetrahidrofuran-3-il)amino)imidazo[1,5-a]pirazin-8(7H)-on;
(R)-7-(4-metoksibenzil)-6-metil-3-(3-metilmorfolino)imidazo[1,5-a]pirazin-8(7H)-on;
(S)-7-(4-metoksibenzil)-6-metil-3-(3-metilmorfolino)imidazo[1,5-a]pirazin-8(7H)-on;
7-(4-metoksibenzil)-6-metil-3-(1,4-oksazepan-4-il)imidazo[1,5-a]pirazin-8(7H)-on;
3-(2,2-dimetilmorfolino)-7-(4-metoksibenzil)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-3-((3aS,6aS)-heksahidro-4H-furo[3,2-b]pirol-4-il)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
7-(3-fluorobenzil)-3-((3aR,6aR)-heksahidro-4H-furo[3,2-b]pirol-4-il)-6-metilimidazo[1,5-a]pirazin-8(7H)-on;
(R)-7-(3-fluorobenzil)-6-metil-3-(tetrahidro-2H-piran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
(S)-7-(3-fluorobenzil)-6-metil-3-(tetrahidro-2H-piran-3-il)imidazo[1,5-a]pirazin-8(7H)-on;
ili farmaceutski prihvatljiva sol bilo kojeg od ovih spojeva.
8. Farmaceutski pripravak prema bilo kojem od zahtjeva 5-7, koji sadrži spoj formule (I) i bilo koji od spojeva navedenih pod stavkom 2) zahtjeva 5, u terapeutski učinkovitim količinama.
9. Farmaceutski pripravak prema bilo kojem od zahtjeva 5-8 za uporabu u liječenju psihijatrijskog i/ili kognitivnog poremećaja.
10. Farmaceutski pripravak za uporabu prema zahtjevu 9, pri čemu je spomenuti psihijatrijski i/ili kognitivni poremećaj odabran od skupine koja se sastoji od poremećaja hiperaktivnosti i deficita pažnje (ADHD), depresije, anksioznosti, narkolepsije, shizofrenije, kognitivnog oštećenja i kognitivnog oštećenja povezanog sa shizofrenijom (CIAS).
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DKPA201600659 | 2016-10-28 | ||
PCT/EP2017/077497 WO2018078038A1 (en) | 2016-10-28 | 2017-10-26 | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
EP17791080.9A EP3532064B1 (en) | 2016-10-28 | 2017-10-26 | Combination treatments comprising imidazopyrazinones for the treatment of psychiatric and/or cognitive disorders |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20201326T1 true HRP20201326T1 (hr) | 2020-11-27 |
Family
ID=60186299
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20201326TT HRP20201326T1 (hr) | 2016-10-28 | 2020-08-25 | Kombinacijska liječenja koja sadrže imidazopirazinone za liječenje psihijatrijskih i/ili kognitivnih poremećaja |
Country Status (29)
Country | Link |
---|---|
US (1) | US10905688B2 (hr) |
EP (1) | EP3532064B1 (hr) |
JP (1) | JP2019536762A (hr) |
KR (1) | KR20190075068A (hr) |
CN (1) | CN109803658A (hr) |
AR (1) | AR109991A1 (hr) |
AU (1) | AU2017350473A1 (hr) |
BR (1) | BR112018013247A2 (hr) |
CA (1) | CA3041607A1 (hr) |
CL (1) | CL2019001091A1 (hr) |
CO (1) | CO2019002909A2 (hr) |
CY (1) | CY1123396T1 (hr) |
DK (1) | DK3532064T3 (hr) |
ES (1) | ES2816005T3 (hr) |
HR (1) | HRP20201326T1 (hr) |
HU (1) | HUE050403T2 (hr) |
IL (1) | IL265635A (hr) |
LT (1) | LT3532064T (hr) |
MA (1) | MA46611B1 (hr) |
ME (1) | ME03821B (hr) |
MX (1) | MX2019004763A (hr) |
PL (1) | PL3532064T3 (hr) |
PT (1) | PT3532064T (hr) |
RS (1) | RS60716B1 (hr) |
RU (1) | RU2019109039A (hr) |
SG (1) | SG11201903770UA (hr) |
SI (1) | SI3532064T1 (hr) |
WO (1) | WO2018078038A1 (hr) |
ZA (1) | ZA201902091B (hr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
WO2018073251A1 (en) | 2016-10-18 | 2018-04-26 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
CN109803653A (zh) | 2016-10-28 | 2019-05-24 | H.隆德贝克有限公司 | 包括给予咪唑并吡嗪酮的组合治疗 |
MX2019004763A (es) | 2016-10-28 | 2019-07-01 | H Lundbeck As | Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos. |
WO2019151274A1 (ja) | 2018-02-01 | 2019-08-08 | 日本たばこ産業株式会社 | 含窒素複素環アミド化合物及びその医薬用途 |
Family Cites Families (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB973361A (en) | 1960-05-11 | 1964-10-28 | Ciba Ltd | Pyrazolo-pyrimidines and process for their manufacture |
DE19709877A1 (de) | 1997-03-11 | 1998-09-17 | Bayer Ag | 1,5-Dihydro-pyrazolo[3,4-d]-pyrimidinon-derivate |
MY144532A (en) | 2001-08-20 | 2011-09-30 | Lundbeck & Co As H | Novel method for down-regulation of amyloid |
DE10238722A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Selektive Phosphodiesterase 9A-Inhibitoren als Arzneimittel zur Verbesserung kognitiver Prozesse |
DE10238723A1 (de) | 2002-08-23 | 2004-03-11 | Bayer Ag | Phenyl-substituierte Pyrazolyprimidine |
DE10238724A1 (de) | 2002-08-23 | 2004-03-04 | Bayer Ag | Alkyl-substituierte Pyrazolpyrimidine |
WO2004099211A1 (de) | 2003-05-09 | 2004-11-18 | Bayer Healthcare Ag | 6-cyclylmethyl- und 6-alkylmethyl-substituierte pyrazolopyrimidine |
WO2006068978A2 (en) | 2004-12-21 | 2006-06-29 | Takeda Pharmaceutial Company Limited | Dipeptidyl peptidase inhibitors |
EP1919287A4 (en) | 2005-08-23 | 2010-04-28 | Intra Cellular Therapies Inc | ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY |
US8012936B2 (en) | 2006-03-29 | 2011-09-06 | New York University | Tau fragments for immunotherapy |
US9006258B2 (en) | 2006-12-05 | 2015-04-14 | Intra-Cellular Therapies, Inc. | Method of treating female sexual dysfunction with a PDE1 inhibitor |
ATE540954T1 (de) | 2007-05-11 | 2012-01-15 | Pfizer | Aminoheterocyclische verbindungen |
WO2009068320A1 (en) | 2007-11-30 | 2009-06-04 | Elbion Gmbh | Aryl and heteroaryl fused imidazo (1,5-a) pyrazines as inhibitors of phosphodiesterase 10 |
UA105362C2 (en) | 2008-04-02 | 2014-05-12 | Бьорингер Ингельхайм Интернациональ Гмбх | 1-heterocyclyl-1, 5-dihydro-pyrazolo [3, 4-d] pyrimidin-4-one derivatives and their use as pde9a modulators |
EA201100446A1 (ru) | 2008-09-08 | 2011-10-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Пиразолопиримидины и их применение для лечения нарушений цнс |
GEP20146046B (en) | 2008-12-06 | 2014-02-25 | Intracellular Therapies Inc | Organic compounds |
TWI404721B (zh) | 2009-01-26 | 2013-08-11 | Pfizer | 胺基-雜環化合物 |
EA032675B1 (ru) | 2009-06-10 | 2019-07-31 | Нью-Йорк Юниверсити | Способ и композиции для лечения болезни альцгеймера и других таупатий |
JP5879336B2 (ja) | 2010-05-31 | 2016-03-08 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
EP3042917B1 (en) | 2010-08-12 | 2018-02-21 | Eli Lilly and Company | Anti-n3pglu amyloid beta peptide antibodies and uses thereof |
AR083058A1 (es) | 2010-09-20 | 2013-01-30 | Envivo Pharmaceuticals Inc | Compuestos de estructura de imidazotriazinona |
EP2619204A4 (en) | 2010-09-21 | 2014-08-27 | Merck Sharp & Dohme | TRIAZOLOPYRAZINONES AS ANTAGONISTS OF P2X7 RECEPTORS |
JO3089B1 (ar) | 2010-11-19 | 2017-03-15 | H Lundbeck As | مشتقات ايميدازول كمثبطات لانزيمات pde10a |
JOP20120083B1 (ar) * | 2011-04-05 | 2021-08-17 | Otsuka Pharma Co Ltd | توليفات تشتمل على بريكس ببرازول أو ملح منه وعقار ثاني للاستخدام في علاج اضطراب cns |
US9499610B2 (en) | 2011-04-08 | 2016-11-22 | H. Lundbeck A/S | Antibodies specific to pyroglutamated Aβ |
JP6051210B2 (ja) | 2011-06-10 | 2016-12-27 | イントラ−セルラー・セラピーズ・インコーポレイテッドIntra−Cellular Therapies, Inc. | 有機化合物 |
CA2886885C (en) * | 2011-10-10 | 2019-07-16 | H. Lundbeck A/S | Pde9i with imidazo pyrazinone backbone |
EP2807163B1 (en) | 2012-01-26 | 2017-03-22 | H. Lundbeck A/S | Pde9 inhibitors with imidazo triazinone backbone |
WO2013192229A1 (en) | 2012-06-18 | 2013-12-27 | Dart Neuroscience (Cayman) Ltd | Substituted pyridine azolopyrimidine - 5 - (6h) - one compounds |
AU2014234990B2 (en) | 2013-03-15 | 2017-11-16 | Intra-Cellular Therapies, Inc. | Organic compounds |
JP5783297B2 (ja) | 2013-08-06 | 2015-09-24 | 株式会社デンソー | 力学量センサ |
UA117695C2 (uk) | 2014-02-19 | 2018-09-10 | Х. Луннбек А/С | 2-аміно-3,5,5-трифтор-3,4,5,6-тетрагідропіридини як інгібітори bace1 для лікування хвороби альцгеймера |
JP5797815B1 (ja) | 2014-06-27 | 2015-10-21 | 細田建設株式会社 | 後施工アンカー及びその施工方法 |
US20160083400A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic guanidine derivative |
US20160083391A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic piperazine derivative |
WO2016042775A1 (en) | 2014-09-18 | 2016-03-24 | Sunovion Pharmaceuticals Inc. | Tricyclic derivative |
TW201629064A (zh) | 2014-10-10 | 2016-08-16 | H 朗德貝克公司 | 作爲pde1抑制劑之三唑並吡酮 |
MA40941A (fr) | 2014-11-10 | 2017-09-19 | H Lundbeck As | 2-amino-5,5-difluoro-6-(fluorométhyl)-6-phényl-3,4,5,6-tétrahydropyridines comme inhibiteurs de bace1 |
CR20170187A (es) | 2014-11-10 | 2018-02-01 | H Lundbeck As | 2-Amino-3,5-difluoro-6-metil-6-fenil-3,4,5,6-tetrahidropiridinas en calidad de inhibidores de BACE1 para el tratamiento de la enfermedad de Alzheimer |
JO3458B1 (ar) | 2014-11-10 | 2020-07-05 | H Lundbeck As | 2- أمينو-6- (دايفلوروميثيل) – 5، 5- ديفلورو-6-فينيل-3،4، 5، 6-تيتراهيدروبيريدين كمثبطات bace1 |
WO2016147659A1 (en) | 2015-03-16 | 2016-09-22 | Sumitomo Dainippon Pharma Co., Ltd. | Bicyclic imidazolo derivative |
TW201643167A (zh) | 2015-04-22 | 2016-12-16 | H 朗德貝克公司 | 作爲pde1抑制劑之咪唑並三酮 |
JO3627B1 (ar) | 2015-04-30 | 2020-08-27 | H Lundbeck As | إيميدازو بيرازينونات على هيئة مثبطات pde1 |
JO3711B1 (ar) | 2015-07-13 | 2021-01-31 | H Lundbeck As | أجسام مضادة محددة لبروتين تاو وطرق استعمالها |
KR20180033524A (ko) | 2015-08-12 | 2018-04-03 | 하. 룬드벡 아크티에셀스카브 | Bace1 저해제로서의 2-아미노-3-플루오로-3-(플루오로메틸)-6-메틸-6-페닐-3,4,5,6-테트라하이드로피리딘 |
CN105254635A (zh) * | 2015-10-30 | 2016-01-20 | 中国药科大学 | 一类咪唑并吡嗪类化合物及其药物组合物和用途 |
AR107456A1 (es) | 2016-02-12 | 2018-05-02 | Lilly Co Eli | Inhibidor de pde1 |
TWI729109B (zh) | 2016-04-12 | 2021-06-01 | 丹麥商H 朗德貝克公司 | 作爲PDE1抑制劑的1,5-二氫-4H-吡唑并[3,4-d]嘧啶-4-酮和1,5-二氫-4H-吡唑并[4,3-c]吡啶-4-酮 |
JP2018076285A (ja) | 2016-09-14 | 2018-05-17 | 大日本住友製薬株式会社 | 二環性イミダゾロ誘導体を含む医薬 |
WO2018073251A1 (en) | 2016-10-18 | 2018-04-26 | H. Lundbeck A/S | Imidazopyrazinones, pyrazolopyrimidinones and pyrazolopyridinones as pde1 inhibitors |
MX2019004763A (es) | 2016-10-28 | 2019-07-01 | H Lundbeck As | Tratamientos de combinacion que comprenden imidazopirazinonas para el tratamiento de trastornos psiquiatricos y/o cognitivos. |
CN109803653A (zh) | 2016-10-28 | 2019-05-24 | H.隆德贝克有限公司 | 包括给予咪唑并吡嗪酮的组合治疗 |
-
2017
- 2017-10-26 MX MX2019004763A patent/MX2019004763A/es unknown
- 2017-10-26 ME MEP-2020-170A patent/ME03821B/me unknown
- 2017-10-26 RU RU2019109039A patent/RU2019109039A/ru not_active Application Discontinuation
- 2017-10-26 HU HUE17791080A patent/HUE050403T2/hu unknown
- 2017-10-26 ES ES17791080T patent/ES2816005T3/es active Active
- 2017-10-26 RS RS20200975A patent/RS60716B1/sr unknown
- 2017-10-26 LT LTEP17791080.9T patent/LT3532064T/lt unknown
- 2017-10-26 WO PCT/EP2017/077497 patent/WO2018078038A1/en unknown
- 2017-10-26 JP JP2019522523A patent/JP2019536762A/ja active Pending
- 2017-10-26 DK DK17791080.9T patent/DK3532064T3/da active
- 2017-10-26 BR BR112018013247A patent/BR112018013247A2/pt not_active Application Discontinuation
- 2017-10-26 CA CA3041607A patent/CA3041607A1/en not_active Abandoned
- 2017-10-26 PT PT177910809T patent/PT3532064T/pt unknown
- 2017-10-26 SI SI201730388T patent/SI3532064T1/sl unknown
- 2017-10-26 PL PL17791080T patent/PL3532064T3/pl unknown
- 2017-10-26 AU AU2017350473A patent/AU2017350473A1/en not_active Abandoned
- 2017-10-26 CN CN201780063182.9A patent/CN109803658A/zh active Pending
- 2017-10-26 MA MA46611A patent/MA46611B1/fr unknown
- 2017-10-26 US US16/345,136 patent/US10905688B2/en active Active
- 2017-10-26 SG SG11201903770UA patent/SG11201903770UA/en unknown
- 2017-10-26 KR KR1020197011509A patent/KR20190075068A/ko not_active Application Discontinuation
- 2017-10-26 EP EP17791080.9A patent/EP3532064B1/en active Active
- 2017-10-27 AR ARP170102997A patent/AR109991A1/es unknown
-
2019
- 2019-03-26 IL IL265635A patent/IL265635A/en unknown
- 2019-03-27 CO CONC2019/0002909A patent/CO2019002909A2/es unknown
- 2019-04-03 ZA ZA2019/02091A patent/ZA201902091B/en unknown
- 2019-04-22 CL CL2019001091A patent/CL2019001091A1/es unknown
-
2020
- 2020-08-24 CY CY20201100788T patent/CY1123396T1/el unknown
- 2020-08-25 HR HRP20201326TT patent/HRP20201326T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
JP2019536762A (ja) | 2019-12-19 |
ME03821B (me) | 2021-04-20 |
CO2019002909A2 (es) | 2019-06-19 |
CN109803658A (zh) | 2019-05-24 |
SI3532064T1 (sl) | 2020-10-30 |
RU2019109039A3 (hr) | 2021-01-29 |
BR112018013247A2 (pt) | 2018-12-04 |
AR109991A1 (es) | 2019-02-13 |
EP3532064B1 (en) | 2020-07-29 |
PL3532064T3 (pl) | 2020-11-16 |
EP3532064A1 (en) | 2019-09-04 |
KR20190075068A (ko) | 2019-06-28 |
SG11201903770UA (en) | 2019-05-30 |
ES2816005T3 (es) | 2021-03-31 |
RS60716B1 (sr) | 2020-09-30 |
MA46611B1 (fr) | 2020-08-31 |
CY1123396T1 (el) | 2021-12-31 |
IL265635A (en) | 2019-05-30 |
LT3532064T (lt) | 2020-09-25 |
US10905688B2 (en) | 2021-02-02 |
RU2019109039A (ru) | 2020-11-30 |
PT3532064T (pt) | 2020-09-03 |
AU2017350473A1 (en) | 2019-04-18 |
MX2019004763A (es) | 2019-07-01 |
DK3532064T3 (da) | 2020-08-24 |
ZA201902091B (en) | 2020-10-28 |
CA3041607A1 (en) | 2018-05-03 |
HUE050403T2 (hu) | 2020-12-28 |
MA46611A (fr) | 2019-09-04 |
WO2018078038A1 (en) | 2018-05-03 |
US20190282571A1 (en) | 2019-09-19 |
CL2019001091A1 (es) | 2019-07-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20201326T1 (hr) | Kombinacijska liječenja koja sadrže imidazopirazinone za liječenje psihijatrijskih i/ili kognitivnih poremećaja | |
HRP20191180T1 (hr) | Imidazopirazinoni kao inhibitori pde1 | |
RU2019108717A (ru) | Комбинированные средства для лечения, предусматривающего введение имидазопиразинонов | |
JP2018514552A5 (hr) | ||
RU2707751C1 (ru) | Пирролопирроловые композиции в качестве активаторов пируваткиназы (pkr) | |
JP6510068B2 (ja) | 新規なビフェニル化合物又はその塩 | |
ES2661003T3 (es) | Quinolinas como moduladores de FGFR quinasa | |
RU2016137169A (ru) | Гетероциклические соединения, способ их получения и их применение | |
ES2441178T3 (es) | Derivados de 2-oxo-1-pirrolidina, procedimientos para prepararlos y el uso terapéutico de los mismos sobre el sistema nervioso central | |
HRP20200556T1 (hr) | Novi (hetero) aril-supstituirani-piperidinil derivati, postupak za njihovu pripravu i farmaceutski pripravci koji ih sadrže | |
RU2018133391A (ru) | 1,5-дигидро-4н-пиразоло[3,4-d]пиримидин-4-оны и 1,5-дигидро-4н-пиразоло[4,3-c]пиридин-4-оны в качестве ингибиторов pde1 | |
EP3601259A1 (en) | Isoquinolines as inhibitors of hpk1 | |
TWI829676B (zh) | 噁二唑暫時受體電位通道抑制劑 | |
JP2017524734A5 (hr) | ||
RU2015100213A (ru) | Замещенные соединения пиридин азолопиримидин-5-(6н)-она | |
RU2017111888A (ru) | Триазолопиразиноны в качестве ингибиторов pde1 | |
AR049521A1 (es) | Derivados de pirrazol - pirimidina | |
EP1796467A2 (en) | Imidazo{4,5-b}pyrazinone inhibitors of protein kinases | |
CA2571627A1 (en) | Substituted aryl-amine derivatives and methods of use | |
RU2017140446A (ru) | Гетероарильное производное или его фармацевтически приемлемая соль, способ их получения и фармацевтическая композиция для профилактики или лечения заболеваний, связанных с pi3 киназами, содержащая данное действующее вещество | |
JP2015526395A5 (hr) | ||
HRP20120105T1 (hr) | Aminoheterociklički spojevi | |
RU2008141761A (ru) | ИНГИБИТОРЫ с-МЕТ ПРОТЕИНКИНАЗЫ | |
HRP20100603T1 (hr) | Derivati pirimidina koji se koriste kao inhibitori pi-3 kinaze | |
KR20200009068A (ko) | 신규 비페닐 화합물 또는 그의 염 |